The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Type I interferon in rheumatic diseases
Open accessAbstract
The type I interferon pathway has been implicated in the pathogenesis of a number of rheumatic diseases, including systemic lupus erythematosus, Sjögren syndrome, myositis, systemic sclerosis, and rheumatoid arthritis. In normal immune responses, type I interferons have a critical role in the defence against viruses, yet in many rheumatic diseases, large subgroups of patients demonstrate persistent activation of the type I interferon pathway. Genetic variations in type I interferon-related genes are risk factors for some rheumatic diseases, and can explain some of the heterogeneity in type I interferon responses seen between patients within a given disease. Inappropriate activation of the immune response via Toll-like receptors and other nucleic acid sensors also contributes to the dysregulation of the type I interferon pathway in a number of rheumatic diseases. Theoretically, differences in type I interferon activity between patients might predict response to immune-based therapies, as has been demonstrated for rheumatoid arthritis. A number of type I interferon and type I interferon pathway blocking therapies are currently in clinical trials, the results of which are promising thus far. This Review provides an overview of the many ways in which the type I interferon system affects rheumatic diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Microglia-dependent synapse loss in type I interferon-mediated lupus
Bialas, A. R., Presumey, J., Das, A., van der Poel, C. E., Lapchak, P. H., Mesin, L., Victora, G., Tsokos, G. C., Mawrin, C., Herbst, R., et al. (2017) · Nature · doi:10.1038/nature22821 · Cited by 197
RetractedPathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2014) · Nature Reviews Immunology · doi:10.1038/nri3581 · Cited by 3,297
Baechler, E. C., Batliwalla, F. M., Karypis, G., Gaffney, P. M., Ortmann, W. A., Espe, K. J., Shark, K. B., Grande, W. J., Hughes, K. M., Kapur, V., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0337679100 · Cited by 2,240
Rissin, D. M., Kan, C. W., Campbell, T. G., Howes, S. C., Fournier, D. R., Song, L., Piech, T., Patel, P. P., Chang, L., Rivnak, A. J., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1641 · Cited by 2,119
Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood
Bennett, L., Palucka, A. K., Arce, E., Cantrell, V., Borvak, J., Banchereau, J., & Pascual, V. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021553 · Cited by 1,958
Innate immune recognition of viral infection
Kawai, T., & Akira, S. (2006) · Nature Immunology · doi:10.1038/ni1303 · Cited by 1,899
Interferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,766
Activated STING in a Vascular and Pulmonary Syndrome
Liu, Y., Jesus, A. A., Marrero, B., Yang, D., Ramsey, S. E., Montealegre Sanchez, G. A., Tenbrock, K., Wittkowski, H., Jones, O. Y., Kuehn, H. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312625 · Cited by 1,412
Cited by
Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response
Wan, D., Jiang, W., & Hao, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00615 · Cited by 270
FLT3 stop mutation increases FLT3 ligand level and risk of autoimmune thyroid disease
Saevarsdottir, S., Olafsdottir, T. A., Ivarsdottir, E. V., Halldorsson, G. H., Gunnarsdottir, K., Sigurdsson, A., Johannesson, A., Sigurdsson, J. K., Juliusdottir, T., Lund, S. H., et al. (2020) · Nature · doi:10.1038/s41586-020-2436-0 · Cited by 137
Discovery of GSK8612, a Highly Selective and Potent TBK1 Inhibitor
Thomson, D. W., Poeckel, D., Zinn, N., Rau, C., Strohmer, K., Wagner, A. J., Graves, A. P., Perrin, J., Bantscheff, M., Duempelfeld, B., et al. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00027 · Cited by 103
Immune Mechanisms in Inflammatory Anemia
Canny, S. P., Orozco, S. L., Thulin, N. K., & Hamerman, J. A. (2023) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101320-125839 · Cited by 65
Metadata
- Authors
- Muskardin, T. L. W., & Niewold, T. B.
- Venue
- Nature Reviews Rheumatology
- Published
- 2018-03-21
- Volume
- 14
- Issue
- 4
- Pages
- 214-228
- ISSN
- 1759-4790 (ISSN-L)
- 1759-4804
- OpenAlex
- W2790466592
- Cited by
- 308
- References
- 152
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Type I interferon in rheumatic diseases. https://app.cochat.ai/papers/10.1038/nrrheum.2018.31
- The paper
- Muskardin, T. L. W., & Niewold, T. B. (2018). Type I interferon in rheumatic diseases. Nature Reviews Rheumatology. https://doi.org/10.1038/nrrheum.2018.31
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
